2012-10-10 21:43:45 - Recently published research from Global Markets Direct, "Pharnext SAS - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Pharnext SAS - Product Pipeline Review - 2012" provides data on the Pharnext SAS's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Pharnext SAS's corporate website, SEC filings, investor presentations and featured press releases, both from Pharnext SAS and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Pharnext SAS - Brief Pharnext SAS overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Pharnext SAS human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Pharnext SAS with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Pharnext SAS's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468583_pharnext_sas_product_pipeline_review_ ..


Reasons to buy

* Evaluate Pharnext SAS's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Pharnext SAS in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Pharnext SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Pharnext SAS.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Pharnext SAS and identify potential opportunities in those areas.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Pharnext SAS Snapshot
Pharnext SAS Overview
Key Information
Key Facts
Pharnext SAS - Research and Development Overview
Key Therapeutic Areas
Pharnext SAS - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pharnext SAS - Pipeline Products Glance
Pharnext SAS Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Pharnext SAS - Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Pharnext SAS - Drug Profiles
Charcot-Marie-Tooth type 1A (CMT-1A)
Product Description
Mechanism of Action
R&D Progress
Drug For Alzheimer's Disease
Product Description
Mechanism of Action
R&D Progress
Drug For Amyotrophic Lateral Sclerosis
Product Description
Mechanism of Action
R&D Progress
Drug For Diabetes Type II
Product Description
Mechanism of Action
R&D Progress
Drug For Hypertension
Product Description
Mechanism of Action
R&D Progress
Drug For Multiple Sclerosis
Product Description
Mechanism of Action
R&D Progress
Drug For Polysystic Kidney Disease
Product Description
Mechanism of Action
R&D Progress
Drug For Toxic Neuropathies
Product Description
Mechanism of Action
R&D Progress
Pharnext SAS - Pipeline Products by Route of Administration
Pharnext SAS - Recent Pipeline Updates
Pharnext SAS - Locations And Subsidiaries
Head Office
Financial Deals Landscape
Pharnext SAS, Deals Summary
Pharnext SAS, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Pharnext Raises Additional $11.2 Million In Venture Financing
Pharnext Secures $6 Million In Series A Financing Round
Pharnext Secures $4 Million In Seed Financing
Partnerships
Ipsen Enters Into Co-Development Agreement With Pharnext
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Pharnext SAS, Key Information
Pharnext SAS, Key Facts
Pharnext SAS - Pipeline by Indication, 2012
Pharnext SAS - Pipeline by Stage of Development, 2012
Pharnext SAS - Monotherapy Products in Pipeline, 2012
Pharnext SAS - Phase II, 2012
Pharnext SAS - Discovery, 2012
Pharnext SAS - Pipeline By Route of Administration, 2012
Pharnext SAS - Recent Pipeline Updates, 2012
Pharnext SAS, Deals Summary
Pharnext Raises Additional $11.2 Million In Venture Financing
Pharnext Secures $6 Million In Series A Financing Round
Pharnext Secures $4 Million In Seed Financing
Ipsen Enters Into Co-Development Agreement With Pharnext

List of Figures
Pharnext SAS - Pipeline by Indication, 2012
Pharnext SAS - Pipeline by Stage of Development, 2012
Pharnext SAS - Monotherapy Products in Pipeline, 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.